Compounds > aglafoline
Page last updated: 2024-11-08

aglafoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aglafoline: a platelet activating factor antagonist; structure given in first source; isolated from Aglaia elliptifolia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aglafolin : A heterotricyclic compound based on a 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a and methoxy groups at C-6 and C-8. A platelet aggregation inhibitor found in Aglaia elliptifolia and Aglaia odorata. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
AglaiagenusA plant genus of the family MELIACEAE. Members contain lariciresinol, pregnanes, insecticidal rocaglamide derivatives and other compounds.[MeSH]MeliaceaeThe mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID393601
CHEMBL ID394528
CHEBI ID65374
SCHEMBL ID748617
MeSH IDM0207723

Synonyms (31)

Synonym
143901-35-3
1h-cyclopenta(b)benzofuran-2-carboxylic acid, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-, methyl ester, (1alpha,2alpha,3beta,3abeta,8bbeta)-
1h-cyclopenta(b)benzofuran-2-carboxylic cid, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-, methyl ester, (1alpha,2alpha,3beta,3abeta,8bbeta)-
nsc695795
methyl rocaglate
CMLD2_000263
CMLDBU00002646
nsc-695795
aglafoline
CHEMBL394528
chebi:65374 ,
aglafolin
methyl (1r,2r,3s,3ar,8bs)-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1h-cyclopenta[b][1]benzofuran-2-carboxylate
methyl (1r,2r,3s,3ar,8bs)-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1h-benzo[b]cyclopenta[d]furan-2-carboxylate
bdbm50397434
methyl 1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1h-benzo[b]cyclopenta[d]furan-2-carboxylate
SCHEMBL748617
CS-5352
HY-19354
rocaglamide j
CCG-102285
AKOS030526537
SR-05000001265-1
sr-05000001265
J-008307
DTXSID50932140
Q27133817
rocaglamide u
(-)-methyl rocaglate
F85339
MS-29150
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Eukaryotic initiation factor 4A-IHomo sapiens (human)EC50 (µMol)0.05000.00080.02700.0900AID704239; AID704240
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcription factor p65Homo sapiens (human)ED5020.00000.00500.04250.0800AID733967
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (81)

Processvia Protein(s)Taxonomy
cytoplasmic translational initiationEukaryotic initiation factor 4A-IHomo sapiens (human)
translational initiationEukaryotic initiation factor 4A-IHomo sapiens (human)
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
RNA cap bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
RNA bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
RNA helicase activityEukaryotic initiation factor 4A-IHomo sapiens (human)
double-stranded RNA bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
mRNA bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
translation initiation factor activityEukaryotic initiation factor 4A-IHomo sapiens (human)
helicase activityEukaryotic initiation factor 4A-IHomo sapiens (human)
protein bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
ATP bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
translation factor activity, RNA bindingEukaryotic initiation factor 4A-IHomo sapiens (human)
ATP hydrolysis activityEukaryotic initiation factor 4A-IHomo sapiens (human)
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusEukaryotic initiation factor 4A-IHomo sapiens (human)
cytoplasmEukaryotic initiation factor 4A-IHomo sapiens (human)
cytosolEukaryotic initiation factor 4A-IHomo sapiens (human)
membraneEukaryotic initiation factor 4A-IHomo sapiens (human)
eukaryotic translation initiation factor 4F complexEukaryotic initiation factor 4A-IHomo sapiens (human)
extracellular exosomeEukaryotic initiation factor 4A-IHomo sapiens (human)
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1100803Antifungal activity against Fusarium avenaceum VIAM MA1512 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis2000Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4
Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID399942Cytotoxicity against human KB cells2004Journal of natural products, Mar, Volume: 67, Issue:3
Cytotoxic constituents of the twigs and leaves of Aglaia rubiginosa.
AID398896Antiplatelet aggregation activity against ADP-induced rabbit platelet assessed as platelet aggregation at 100 ug/mL relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID704238Selectivity index, ratio of EC50 for eIF4FA in human MDA-MB-231 cells transfected with tubulin 5'-UTR-luciferase construct to EC50 for eIF4FA in human MDA-MB-231 cells transfected with c-myc- 5'-UTR-luciferase construct by differential translation assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID398903Cytotoxicity against mouse P388 cells1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID398899Antiplatelet aggregation activity against collagen-induced rabbit platelet assessed as platelet aggregation at 100 ug/mL relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID398902Cytotoxicity against human HCT8 cells1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID733969Cytotoxicity against human HT-29 cells2013Journal of natural products, Mar-22, Volume: 76, Issue:3
Bioactive flavaglines and other constituents isolated from Aglaia perviridis.
AID733967Inhibition of NF-kappaB p65 (unknown origin) by ELISA2013Journal of natural products, Mar-22, Volume: 76, Issue:3
Bioactive flavaglines and other constituents isolated from Aglaia perviridis.
AID292727Inhibition of NF-kappaB by ELISA assay2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Ponapensin, a cyclopenta[bc]benzopyran with potent NF-kappaB inhibitory activity from Aglaia ponapensis.
AID398904Cytotoxicity against human RPMI7951 cells1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID398900Cytotoxicity against human KB cells1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID1272157Binding affinity to eIF4A1 in mouse embryonic fibroblasts at 20 uM by streptavidin pulldown assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II.
AID704237Growth inhibition of human MDA-MB-231 cells incubated for 72 hrs by MTS assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID399943Cytotoxicity against human LNCAP cells2004Journal of natural products, Mar, Volume: 67, Issue:3
Cytotoxic constituents of the twigs and leaves of Aglaia rubiginosa.
AID1100805Antifungal activity against Magnaporthe grisea VIAM MA1627 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis2000Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4
Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID704239Inhibition of eIF4FA in human MDA-MB-231 cells transfected with tubulin 5'-UTR-luciferase construct assessed as reduction in translation initiation incubated for 24 hrs by differential translation assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID1100804Antifungal activity against Alternaria citri CBS 192.81; VIAM MA1628 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis2000Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4
Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID398898Antiplatelet aggregation activity against platelet activating factor-induced rabbit platelet assessed as platelet aggregation at 100 ug/mL relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID398897Antiplatelet aggregation activity against arachidonic acid-induced rabbit platelet assessed as platelet aggregation at 100 ug/mL relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID704240Inhibition of eIF4FA in human MDA-MB-231 cells transfected with c-myc- 5'-UTR-luciferase construct assessed as reduction in translation initiation incubated for 24 hrs by differential translation assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
AID1272158Binding affinity to eIF4A2 in mouse embryonic fibroblasts at 20 uM by streptavidin pulldown assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II.
AID398905Cytotoxicity against human TE671 cells1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID399940Cytotoxicity against human Col2 cells2004Journal of natural products, Mar, Volume: 67, Issue:3
Cytotoxic constituents of the twigs and leaves of Aglaia rubiginosa.
AID733968Cytotoxicity against human CCD-112CoN cells2013Journal of natural products, Mar-22, Volume: 76, Issue:3
Bioactive flavaglines and other constituents isolated from Aglaia perviridis.
AID399945Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells2004Journal of natural products, Mar, Volume: 67, Issue:3
Cytotoxic constituents of the twigs and leaves of Aglaia rubiginosa.
AID1272156Inhibition of e1F4A1 (unknown origin) in rabbit reticulocyte assessed as capped-dependent translation incubated for 1 hr by dual glo luciferase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II.
AID398901Cytotoxicity against human A549 cells1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID399941Cytotoxicity against HUVEC2004Journal of natural products, Mar, Volume: 67, Issue:3
Cytotoxic constituents of the twigs and leaves of Aglaia rubiginosa.
AID399944Cytotoxicity against human Lu1 cells2004Journal of natural products, Mar, Volume: 67, Issue:3
Cytotoxic constituents of the twigs and leaves of Aglaia rubiginosa.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (15.38)18.2507
2000's3 (23.08)29.6817
2010's7 (53.85)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.36 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.110L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.0710pyrrole;
secondary amine
acetyl bromide
[no description available]		2.0710
3-hydroxyflavone
3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.		2.0710flavonols;
monohydroxyflavone
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.0210delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
benomyl
[no description available]		210aromatic amide;
benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		acaricide;
anthelminthic drug;
antifungal agrochemical;
microtubule-destabilising agent;
tubulin modulator
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.0710benzenes;
phenyl acetates
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.4520taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		1.9910beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.		1.98102-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
biotin
vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.		2.1310biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		4.7590
lupeol
[no description available]		3.4110pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite
rocaglamide
rocaglamide: RN refers to (1alpha,2alpha,3beta,3abeta,8bbeta)-isomer; isolated from stems of Aglaia elliptifolia; structure given in first source. rocaglamide : An organic heterotricyclic compound that is 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan substituted by hydroxy groups at positions 1 and 8b, methoxy groups at positions 6 and 8, a 4-methoxyphenyl group at position 3a, a phenyl group at position 3 and a N,N-dimethylcarbamoyl group at position 1. Isolated from Aglaia odorata and Aglaia duperreana, it exhibits antineoplastic activity.		3.1350monocarboxylic acid amide;
monomethoxybenzene;
organic heterotricyclic compound		antileishmanial agent;
antineoplastic agent;
metabolite
rocaglaol
rocaglaol: a cytotoxic cyclopenta(b)benzofuran from the bark of Aglaia crassinervia; structure in first source		2.4420
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		2.0210(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
eriodictyol
eriodictyol: structure. eriodictyol : A tetrahydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5, 7, 3' and 4' respectively.		2.02103'-hydroxyflavanones;
tetrahydroxyflavanone
doxorubicin hydrochloride
[no description available]		1.9910anthracycline
steviol
steviol: aglucon of stevioside; RN given refers to (4alpha)-isomer. steviol : An ent-kaurane diterpenoid that is 5beta,8alpha,9beta,10alpha-kaur-16-en-18-oic acid in which the hydrogen at position 13 has been replaced by a hydroxy group.		3.4110bridged compound;
ent-kaurane diterpenoid;
monocarboxylic acid;
tertiary allylic alcohol;
tetracyclic diterpenoid		antineoplastic agent
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		3.4110stilbene
sesquiterpenes
[no description available]		3.4110
scopoletin
[no description available]		2.4320hydroxycoumarinplant growth regulator;
plant metabolite
thromboxane b2
Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.		1.9810thromboxanes Bhuman metabolite;
mouse metabolite
vinblastine sulfate
[no description available]		1.9910
7-epiclusianone
7-epiclusianone: from Rheedia gardneriana; structure in first source. 7-epiclusianone : An enone that is a tetraprenyl benzophenone derivative isolated from Rheedia gardneriana and Garcinia brasiliensis. It exhibits anti-allergic, antibacterial, trypanocidal and vasodilating activities.		3.4110
rocagloic acid
rocagloic acid: from leaves of Aglaia elliptifolia: structure in first source		2.4620
pestalotiopsin a
pestalotiopsin A: structure in first source		3.4110
episilvestrol
episilvestrol: isolated from the fruit and twig of Aglaia silvestris; structure in first source. epi-silvestrol : An organic heterotricyclic compound that is a 5'''-epimer of silvestrol. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.		2.1310dioxanes;
ether;
methyl ester;
organic heterotricyclic compound		antineoplastic agent;
metabolite
silvestrol
silvestrol: isolated from the fruit and twig of Aglaia silvestris. silvestrol : An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.		2.520dioxanes;
ether;
methyl ester;
organic heterotricyclic compound		antineoplastic agent;
metabolite
goniomitine
goniomitine: from root bark of Gonioma malagasy; structure in first source		3.4110monoterpenoid indole alkaloid
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		02.0710
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.0710